• Dr. Smith on Syndromic Testing and Patient Satisfaction

  • 2022/06/13
  • 再生時間: 12 分
  • ポッドキャスト

Dr. Smith on Syndromic Testing and Patient Satisfaction

  • サマリー

  • In this episode, Dr. Smith explores a case study where he utilized the BIOFIRE® Respiratory Panel to help identify whether a pediatric patient had an exacerbation of allergic rhinitis or a respiratory infection. He wraps up by showing how BIOFIRE respiratory solutions have helped improve patient satisfaction.

    This podcast was sponsored by bioMerieux.

    More about the power of PCR diagnostic testing in point-of-care clinics here.

    This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

In this episode, Dr. Smith explores a case study where he utilized the BIOFIRE® Respiratory Panel to help identify whether a pediatric patient had an exacerbation of allergic rhinitis or a respiratory infection. He wraps up by showing how BIOFIRE respiratory solutions have helped improve patient satisfaction.

This podcast was sponsored by bioMerieux.

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Dr. Smith on Syndromic Testing and Patient Satisfactionに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。